Bayat M, Nahand JS. Exosomal miRNAs: the tumor’s Trojan horse in selective metastasis. Mol Cancer. 2024;23:167.

Article  PubMed  PubMed Central  Google Scholar 

Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22:48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. 2019;2:301–11.

Article  Google Scholar 

Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature. 2016;534:402–6.

Article  PubMed  CAS  Google Scholar 

Leuzzi G, Vasciaveo A, Taglialatela A, Chen X, Fireston TM, Hickman AR, et al. SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell. 2024;187:861–81.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen Y, Jia K, Chong X, Xie Y, Jiang L, Peng H, et al. Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer. Mol Cancer 2024;23:169.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Federico AD, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann Oncol. 2024;35:902–13.

Article  PubMed  Google Scholar 

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.

Article  PubMed  PubMed Central  Google Scholar 

Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14:10.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy. Mol Cancer. 2024;23:183.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 2024;23:108.

Article  PubMed  PubMed Central  Google Scholar 

Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17:54.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kim MS, Xu A, Haslam A, Prasad V. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020. Int J Cancer. 2022;150:1905–10.

Article  PubMed  CAS  Google Scholar 

Bahamonde CS, Herrero SL, Díaz RG, Pérez AM, García CA, Rodrigo JP, et al. Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy. Mol Cancer. 2023;22:142.

Article  Google Scholar 

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101–5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng 2019;3:306–17.

Article  PubMed  CAS  Google Scholar 

Chen J, Zhou Z, Zheng C, Liu Y, Hao R, Ji X, et al. Chitosan oligosaccharide regulates AMPK and STAT1 pathways synergistically to mediate PD-L1 expression for cancer chemoimmunotherapy. Carbohydr Polym. 2022;277:118869.

Article  PubMed  CAS  Google Scholar 

Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71:606–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ferris SP, Kodali VK, Kaufman RJ. Glycoprotein folding and quality-control mechanisms in protein-folding diseases. Dis Model Mech. 2014;7:331–41.

Article  PubMed  PubMed Central  Google Scholar 

Xu C, Ng DT. Glycosylation-directed quality control of protein folding. Nat Rev Mol Cell Biol. 2015;16:742–52.

Article  PubMed  CAS  Google Scholar 

Zappasodi R, Merghoub T. Jedd DW. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;34:690.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lu Y, Sun Y, Drummer C, Nanayakkara GK, Shao Y, Saaoud F, et al. Increased acetylation of H3K14 in the genomic regions that encode trained immunity enzymes in lysophosphatidylcholine-activated human aortic endothelial cells – Novel qualification markers for chronic disease risk factors and conditional DAMPs. Redox Bio. 2019;24:101221.

Article  CAS  Google Scholar 

Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, et al. Removal of n-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell. 2019;36:168–78.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu Y, Zhou Z, Hou J, Xiong W, Kim H, Chen J, et al. Tumor selective metabolic reprogramming as a prospective PD-L1 depression strategy to reactivate immunotherapy. Adv Mater. 2022;34:2206121.

Article  CAS  Google Scholar 

Berz D. A pilot study on the anticancer effects of novel candidate agent COH-SR4 in lung cancer. J Clin Oncol. 2012;30:28.

Article  Google Scholar 

Huang J, Kong R, Li Y, Yan N, Wu Y, Qiu Z, et al. Feedback enhanced tumor targeting delivery of albumin-based nanomedicine to amplify photodynamic therapy by regulating AMPK signaling and inhibiting GSTs. Chin Chem Lett. 2024;35:109254.

Article  CAS  Google Scholar 

Escobar G, Tooley K, Oliveras JP, Huang L, Cheng H, Bookstaver ML, et al. Tumor immunogenicity dictates reliance on TCF1 in CD8+ T cells for response to immunotherapy. Cancer Cell. 2023;41:1662–79.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Teng Y, Yang Z, Peng Y, Yang Y, Chen S, Li J, et al. Endoplasmic reticulum stress nano-orchestrators for precisely regulated immunogenic cell death as potent cancer vaccines. Adv Health Mater. 2024;14:2401851.

Article  Google Scholar 

Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res. 2021;31:5–16.

Article  PubMed  CAS  Google Scholar 

Han C, Xiao S, Xing Z, Xu X, Wang M, Han X, et al. NADPH oxidases-inspired reactive oxygen biocatalysts with electron-rich Pt sites to potently amplify immune checkpoint blockade therapy. Adv Mater. 2025;37:e2407644.

Xiang Y, Chen L, Liu C, Yi X, Li L, Huang Y. Redirecting chemotherapeutics to the endoplasmic reticulum increases tumor immunogenicity and potentiates anti-PD-L1 therapy. Small. 2022;18:2104591.

Article  CAS